Page last updated: 2024-10-25

deferoxamine and Leukemia, Lymphoblastic, Acute, T Cell

deferoxamine has been researched along with Leukemia, Lymphoblastic, Acute, T Cell in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benadiba, J1
Rosilio, C1
Nebout, M1
Heimeroth, V1
Neffati, Z1
Popa, A1
Mary, D1
Griessinger, E1
Imbert, V1
Sirvent, N1
Peyron, JF1

Other Studies

1 other study available for deferoxamine and Leukemia, Lymphoblastic, Acute, T Cell

ArticleYear
Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:6

    Topics: Animals; Antigens, CD; Apoptosis; Asparaginase; Cell Line, Tumor; Cell Survival; Cells, Cultured; Ch

2017